The AI landscape doesn't move in one direction — it lurches. Some techniques leap from experiment to table stakes in a single quarter; others stall against regulatory walls, technical ceilings, or organisational inertia that no amount of hype can dislodge. Knowing which is which is the hard part. The State of Play cuts through the noise with a rigorously maintained index of AI techniques across every major business domain — classified by maturity, evidenced by real-world adoption, and updated daily so you always know where you stand relative to the field. Stop guessing. Start knowing.
A daily newsletter distilling the past two weeks of movement in a domain or two — delivered to your inbox while the index updates in the background.
Each dot marks the weighted maturity of practices within a domain — hover for a brief summary, click for more detail
AI that continuously monitors sources for new information on defined topics and alerts users to significant developments. Includes automated literature watch and competitive signal monitoring; distinct from deep research which conducts one-off investigations rather than ongoing surveillance.
Continuous research monitoring and alerting has transitioned from second-wave pilots into standardised operational practice across pharma, healthcare, and enterprise contexts. The ecosystem shows clear signs of maturation: major platforms (DistillerSR, Sorcero, Nested Knowledge, MadeAi) have moved past experimental deployments to governance-focused standardisation, regulatory authorities (FDA) have operationalised automated signal detection, and case studies document substantial productivity gains (50-95% reduction in manual labour, 98% faster screening cycles). Yet the transition remains incomplete and uneven. Alert fatigue and threshold-tuning overhead continue to dominate deployment friction; most organisations still lack the operational discipline to sustain continuous monitoring at scale. The technology is proven. The limiting factor is not capability but organisational willingness to invest in the governance, training, and workflow redesign required to make alerts valuable rather than noisy.
Ecosystem maturity is advancing rapidly with expansion beyond pharma into regulated medical device and financial services contexts. DistillerSR operates at significant scale with 250+ customers, including 80% of top pharma and medical device companies, delivering 70% reductions in screening time. Sorcero's $42.5M Series B, customer base spanning one-third of top-30 global pharma, and product expansion (Medical Affairs suite, Congress Intelligence) confirm sustained enterprise momentum. Regulatory intelligence platforms now mature: Flinn.ai (deployed at 100+ MedTech manufacturers) automates continuous monitoring of regulations across 120+ jurisdictions with AI-driven impact assessment; Qoniq case study documents EU IVDR-driven deployment at diagnostics company, automating weekly surveillance cycles with deduplication and relevance triage. CoVigilAI covers 154+ countries with 100+ language support; pharmacovigilance systems screen 2.5M+ regulatory articles annually with 99% adverse event capture. The FDA's Elsa tool is operational. Healthcare deployments show validated outcomes: Houston Methodist's 8-hospital rollout achieved 95% device utilisation and four-hour nursing shift savings; Cleveland Clinic's COSMOS study demonstrated that threshold tuning reduces alert frequency to one per eight hours. Academic deployments are expanding — Oncoscope-AI's Living SLR system automates oncology literature monitoring across 3,898 studies with 98.6% faster daily update cycles. Evidence-synthesis and medical writing are consolidating around continuous platforms (CiteMed, BiomchBERT).
Industry signals standardisation inflection. ISPOR 2026's "Beyond the Bots" panel brings together market leaders (DistillerSR, Nested Knowledge, MadeAi) to address second-phase concerns: reproducibility, auditability, version control, validation, and governance frameworks. Regulatory authorities now expect rigorous validation, clear SOPs, comprehensive audit trails, and human oversight as baseline operational requirements, not optional enhancements.
Yet adoption remains concentrated. Alert fatigue and threshold-tuning overhead persist as primary barriers outside pharma/healthcare/regulatory. A 2025 telemonitoring study showed modest adjustments (5-10 mmHg) halve manual alert processing; simultaneously, 90% of security teams report excessive alert volume and 67% of organisations have critical monitoring gaps. The pattern is consistent: technology maturity is high, but organisational readiness for continuous governance is low. Platforms expand into new domains (buyer-intent monitoring via RevenueSignal.io, competitive signals via SiteSignal, congress monitoring via Sorcero Congress Intelligence), but each expansion surfaces the same friction: threshold tuning and alert optimisation demand sustained operational discipline most organisations lack.
— Production platform continuously monitoring international regulations, guidelines, and standards for medical devices with real-time change detection and AI-driven impact assessment. Deployed across 100+ MedTech manufacturers globally with automated relevance filtering.
— Molecular diagnostics company deployed continuous AI-powered literature surveillance to meet EU IVDR requirements, automating daily scheduled searches, deduplication, and triage. Reduced manual time burden from 25-30 hours/week to automated weekly cadence with weekly monitoring coverage.
— Comprehensive guide covering AI applications in continuous drug safety monitoring including automated literature scanning of journals and regulatory databases, NLP-based case intake and duplicate detection, and continuous benefit-risk assessment with human-in-the-loop governance.
— Describes continuous monitoring of regulatory updates across 120+ markets with automated alerting via platforms (RegDesk, Freyr RegIntel, Centraleyes) and relevance-based classification, demonstrating operational deployment of continuous research monitoring in regulatory affairs.
— Conference presentation on practical AI-enabled continuous signal detection scaling drug safety monitoring. Covers NLP clustering and Bayesian methods for prioritizing ICSR cases while maintaining human accountability, addressing operational deployment at scale.
— Vendor perspective on real-world challenges in continuous social media monitoring. Documents signal detection scaling to unstructured, decentralized sources (Reddit, WhatsApp, symptom checkers) but judgment frameworks lag detection capability—signaling maturity inflection tension.
— Practitioner guide documenting continuous literature monitoring for drug safety across PubMed/EMBASE with automated signal detection. Named platforms (IQVIA, Oracle, ArisGlobal) reduce ICSR processing by 70-85% and intake-to-submission time from 15+ days to under 5 days.
— Peer-reviewed review documenting shift from reactive to proactive AI-driven pharmacovigilance. Continuous monitoring across wearables, social media, and EHRs enables faster signal detection; adoption advancing significantly across US, EU, China, India.